{"title":"环孢素滴眼液治疗晶格型角膜营养不良1例。","authors":"Hasan Al-Hawasli, Raghid Tarbouche","doi":"10.1097/MS9.0000000000003625","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction and importance: </strong>To report a successful treatment of lattice corneal dystrophy type 1 (LCD1) using topical cyclosporine (CsA) eye drop emulsion 0.05%.</p><p><strong>Case presentation: </strong>A 48-year-old female patient presented with bilateral LCD1characterized by corneal stromal lattice lines and visual symptoms. The patient was treated with topical CsA 0.05% twice daily for 3 months, followed by once daily for another 3 months.</p><p><strong>Clinical discussion: </strong>Following treatment, the patient experienced a significant improvement in symptoms and resolution of corneal opacities in the treated eye.</p><p><strong>Conclusion: </strong>This case report demonstrates the potential efficacy of topical CsA as a novel treatment option for LCD1, offering a noninvasive approach to manage symptoms and improve visual function. Further studies are needed to confirm these findings.</p>","PeriodicalId":8025,"journal":{"name":"Annals of Medicine and Surgery","volume":"87 9","pages":"6127-6130"},"PeriodicalIF":1.6000,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12401456/pdf/","citationCount":"0","resultStr":"{\"title\":\"Cyclosporine eye drops in lattice corneal dystrophy type 1: case report.\",\"authors\":\"Hasan Al-Hawasli, Raghid Tarbouche\",\"doi\":\"10.1097/MS9.0000000000003625\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction and importance: </strong>To report a successful treatment of lattice corneal dystrophy type 1 (LCD1) using topical cyclosporine (CsA) eye drop emulsion 0.05%.</p><p><strong>Case presentation: </strong>A 48-year-old female patient presented with bilateral LCD1characterized by corneal stromal lattice lines and visual symptoms. The patient was treated with topical CsA 0.05% twice daily for 3 months, followed by once daily for another 3 months.</p><p><strong>Clinical discussion: </strong>Following treatment, the patient experienced a significant improvement in symptoms and resolution of corneal opacities in the treated eye.</p><p><strong>Conclusion: </strong>This case report demonstrates the potential efficacy of topical CsA as a novel treatment option for LCD1, offering a noninvasive approach to manage symptoms and improve visual function. Further studies are needed to confirm these findings.</p>\",\"PeriodicalId\":8025,\"journal\":{\"name\":\"Annals of Medicine and Surgery\",\"volume\":\"87 9\",\"pages\":\"6127-6130\"},\"PeriodicalIF\":1.6000,\"publicationDate\":\"2025-07-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12401456/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Annals of Medicine and Surgery\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1097/MS9.0000000000003625\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/9/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Medicine and Surgery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/MS9.0000000000003625","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/9/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
Cyclosporine eye drops in lattice corneal dystrophy type 1: case report.
Introduction and importance: To report a successful treatment of lattice corneal dystrophy type 1 (LCD1) using topical cyclosporine (CsA) eye drop emulsion 0.05%.
Case presentation: A 48-year-old female patient presented with bilateral LCD1characterized by corneal stromal lattice lines and visual symptoms. The patient was treated with topical CsA 0.05% twice daily for 3 months, followed by once daily for another 3 months.
Clinical discussion: Following treatment, the patient experienced a significant improvement in symptoms and resolution of corneal opacities in the treated eye.
Conclusion: This case report demonstrates the potential efficacy of topical CsA as a novel treatment option for LCD1, offering a noninvasive approach to manage symptoms and improve visual function. Further studies are needed to confirm these findings.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
